145 related articles for article (PubMed ID: 27564459)
1. Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.
Angelopoulou MK; Asimakopoulos JV; Galani Z; Levidou G; Roumelioti M; Vassilakopoulos TP; Korkolopoulou P; Panayiotidis P
Blood Cancer J; 2016 Aug; 6(8):e461. PubMed ID: 27564459
[No Abstract] [Full Text] [Related]
2. Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
Shune L; Cayci Z; Rogosheske J; Brunstein C; Ustun C
Leuk Res; 2012 Jun; 36(6):e131-2. PubMed ID: 22444689
[No Abstract] [Full Text] [Related]
3. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
Simpson E; O'Brien SG; Reilly JT
Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
[No Abstract] [Full Text] [Related]
4. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
5. More about imatinib and nilotinib combination therapy in chronic myeloid leukemia.
Gómez-Almaguer D; Tarín-Arzaga L; Cantú-Rodríguez O; Ceballos-López A
Acta Haematol; 2013; 129(1):18-9. PubMed ID: 22986736
[No Abstract] [Full Text] [Related]
6. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Silver RT; Cortes J; Waltzman R; Mone M; Kantarjian H
Haematologica; 2009 May; 94(5):743-4. PubMed ID: 19407320
[No Abstract] [Full Text] [Related]
7. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
[No Abstract] [Full Text] [Related]
8. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
11. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
12. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
13. Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia.
Wiernik PH; Baig MA; Lee SH; Dutcher JP; Paietta E; Racevskis J
Clin Adv Hematol Oncol; 2011 Mar; 9(3):242-8. PubMed ID: 21475132
[No Abstract] [Full Text] [Related]
14. Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
Westfall DE; Zhang L; Song S; Lee S
Arch Pathol Lab Med; 2008 Jun; 132(6):1021-5. PubMed ID: 18517263
[TBL] [Abstract][Full Text] [Related]
15. Basophilic blast phase of chronic myelogenous leukemia.
Babiker HM; Proytcheva M
Blood; 2014 Oct; 124(15):2464. PubMed ID: 25436261
[No Abstract] [Full Text] [Related]
16. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
Breccia M; Nanni M; Mancini F; Russo E; Mecarocci S; Alimena G
Haematologica; 2004 Apr; 89(4):ECR11. PubMed ID: 15075103
[No Abstract] [Full Text] [Related]
17. [Initial therapy of imatinib mesylate for extramedullary T lymphoblastic crisis of chronic myeloid leukemia: a case report and review of the literature].
He HS; Su GP; Chen BB
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):477-8. PubMed ID: 22213870
[No Abstract] [Full Text] [Related]
18. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
[TBL] [Abstract][Full Text] [Related]
19. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
[TBL] [Abstract][Full Text] [Related]
20. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Xu Y; Wahner AE; Nguyen PL
Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
